Home » EPIC Archives: AVCT

AVCT News Archives

Shaping the Future of Cancer Therapy

Avacta Group Plc

A New Approach is Needed Avacta has two proprietary therapeutic platforms positioning the company uniquely well to address the gap in cancer immunotherapies Affimer – Alternative to anti-bodies 10x smaller ...

Read Article »

An Introduction to Affimer Technology

Avacta Group Plc

The Affimer is a revolutionary new engineered affinity protein. This video animation gives an overview of some of the key benefits, features and applications of Affimer technology. It explains why ...

Read Article »

What Is Cancer Immunotherapy?

Avacta Group Plc

Cancer immunotherapy involves empowering the patient’s immune system to recognize, attack and destroy cancer cells. Since cancer cells arise from healthy cells, it can be hard for the immune system to differentiate ...

Read Article »

Avacta Group Plc Turner Pope Investor Evening

Avacta Group Plc

Avacta Group Plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has today announced that the Group’s Chief Executive, Alastair Smith, will be presenting at an investor evening hosted by Turner Pope Investments on Wednesday, ...

Read Article »